|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 14/605 | (2006.01) |
| C07K 14/605 | (2013.01) | ||
| A61K 38/26 | (2006.01) | ||
| A61K 38/00 | (2013.01) | ||
| A61P 3/04 | (2018.01) | ||
| A61P 3/10 | (2018.01) | ||
| A61K 47/542 | (2017.08) |
| (11) | Number of the document | 3551651 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17832211.1 |
| Date of filing the European patent application | 2017-12-11 | |
| (97) | Date of publication of the European application | 2019-10-16 |
| (45) | Date of publication and mention of the grant of the patent | 2024-03-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2017/082290 |
| Date | 2017-12-11 |
| (87) | Number | WO 2018/104561 |
| Date | 2018-06-14 |
| (30) | Number | Date | Country code |
| PA201600757 | 2016-12-09 | DK |
| (72) |
DUE LARSEN, Bjarne , DK
GRIFFIN, Jonathan , SE
GIEHM, Lise , DK
EDWARDS, Alistair Vincent Gordon , DK
|
| (73) |
Zealand Pharma A/S ,
Sydmarken 11, 2860 Søborg,
DK
|
| (54) | ACYLATED GLP-1/GLP-2 DUAL AGONISTS |
| ACYLATED GLP-1/GLP-2 DUAL AGONISTS |